Breath of Life Pharma
Cannabis-related Products
Company Overview
Snapshot
Founded in January 2007, Breath of Life Pharma operates with 11–50 employees. The company has raised $35 million across two funding rounds from four investors. In April 2025, the company ceased to operate.
Business overview
Breath of Life Pharma (BOL Pharma) develops cannabinoid-based drugs and botanical-derived products to improve patient health. The company cultivates proprietary cannabis strains, operates certified labs, and owns a plant and distribution center. BOL Pharma targets the medical cannabis, wellness, and pharmaceutical markets. Its pharmaceutical division launched a spinoff focused on an inhaler based on a Kindeva drug delivery platform, featuring a pressurized metered dose inhaler (pMDI) containing cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) for multiple sclerosis-related neuropathic pain, with plans for additional indications like chemotherapy-induced and HIV-induced neuropathic pain. This IP-protected device offers an efficient and rapid administration route, bypassing gastrointestinal absorption and first-pass hepatic metabolism.
Strategic signal
In April 2025, Breath of Life Pharma ceased to operate, indicating a significant and negative shift in its business trajectory. This event signals to investors and innovation teams that the company's previous efforts in the medical cannabis and pharmaceutical sectors have concluded, marking an end to its operations and product development.
Log in to access full profile ›Company Intelligence Q&A
- What is the current operational status of Breath of Life Pharma?
- Breath of Life Pharma ceased to operate in April 2025.
- When did Breath of Life Pharma sign an agreement with Kindeva for inhaled cannabinoid products?
- In December 2020, Kindeva and BOL Pharma signed an agreement for the development of inhaled cannabinoid products.
- What was the outcome of the proposed Canadian IPO for Breath of Life Pharma?
- In June 2019, Israeli Cannabis Company BOL delayed its Toronto IPO and slashed 17% off its pre-IPO valuation.
- When did Breath of Life Pharma complete Israel's first cannabis export?
- In January 2020, Israel's first cannabis export was completed as LYPHE Group imported products from Breath of Life Pharma into the UK.
- Which investors participated in Breath of Life Pharma's October 2018 funding round?
- In October 2018, Breath of Life Pharma received funding from Gandyr Investments and OurCrowd.